The purpose of this Funding Opportunity Announcement (FOA) is to support preclinical development and demonstration of safe, effective, and non-addictive device-based technologies and approaches to treat pain. The goal of the program is to demonstrate treatment using credible neural targets for device-based interventions and/or diagnostics for pain, building upon the latest mechanistic knowledge about the anatomy and physiology of central, spinal, and peripheral pathways involved in pain. Awarded activities will facilitate the translation of new devices up to the stage of readiness for first in human (FIH) clinical trials by overcoming key challenges identified during preliminary proof-of-concept studies. The scope of the program includes technology development and optimization, and studies to prepare for approvals for human use. This is a milestone-driven cooperative agreement program and will involve participation of NIH program staff in the development of the project plan and monitoring of research progress.
Companion FOAs:
RFA-RM-19-001, U01 Research Project--Cooperative Agreements
RFA-NS-19-016, UG3/UH3 Exploratory/Developmental Phased Award Cooperative Agreement
RFA-NS-19-017, U44 Small Business Innovation Research (SBIR) Cooperative Agreements - Phase II
RFA-NS-19-018, UH3 Exploratory/Developmental Cooperative Agreement Phase II
PAR-18-494, UG3/UH3 Exploratory/Developmental Phased Award Cooperative Agreement
RFA-AR-19-028, UH2/UH3 Exploratory/Developmental Phased Award Cooperative Agreement
Deadlines:
RFA-EB-18-003 Expiration Date February 23, 2021
Application budgets are not limited but need to reflect the actual needs of the proposed project. Budgets should rarely exceed $500,000 direct cost per year.
The scope of the proposed project should determine the project period. The maximum project period is three years of support.
